Non invasive approaches to the earlier detection of disease
We have an active clinical diagnostics pipeline across oncology and inflammatory diseases.
Lung cancer is the most common cancer in the world with an estimated 1.8 million new cases and 1.6 million deaths each year. LuCID aims to develop a breath test for the early detection of lung cancer. LuCID is the world's largest breath-based clinical trial, recruiting up to 4,000 patients in 26 hospitals across Europe.
Asthma is the most common chronic airway disease in the world. We are working with clinical partners to develop breath-based biomarkers that move asthma treatment from trial and error to matching the right patient to the right treatment.
Owlstone Medical’s technology for the early detection of colorectal cancer has the potential to save up to 75,000 lives per year in the EU alone. Our 1,400 patient study in collaboration with Warwick University is paving the way for earlier diagnosis.
Owlstone Medical is working in collaboration with leading cancer researchers at the Cancer Research UK (CRUK) Cambridge Centre on a large scale clinical study aiming to identify breath based biomarkers to improve the earlier detection and diagnosis of multiple different cancer types.